Tag : ADOLESCENTS

CONFERENCE UPDATE

The impact of secukinumab on mental well-being in patients with moderate to severe HS: Post-hoc analysis of the SUNSHINE/SUNRISE trials
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that significantly impacts patients' quality of life (QoL). Individuals with HS often experience comorbidities, including psychiatric conditions such as depression and anxiety, with recent findings indicating they are about twice as likely to develop these disorders compared to those without HS. Secukinumab has shown sustained efficacy in moderate to severe HS in the SUNSHINE and SUNRISE phase 3 trials, improving QoL while maintaining a favorable safety profile over one year.